Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene:: Impairment of its promoter activity

被引:123
作者
Pitarque, M
von Richter, O
Oke, B
Berkkan, H
Oscarson, M
Ingelman-Sundberg, M
机构
[1] Karolinska Inst, IMM, Div Mol Toxicol, Inst Environm Med, S-17177 Stockholm, Sweden
[2] Univ Istanbul, Fac Pharm, Dept Biochem, TR-34452 Istanbul, Turkey
关键词
coumarin; nicotine; lung cancer; gene transcription; genetic polymorphism; DASH;
D O I
10.1006/bbrc.2001.4990
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human cytochrome P450 2A6 (CYP2A6) constitutes the major nicotine oxidase, and large interindividual differences are seen in the levels of this enzyme, to a great extent caused by the distribution of several different polymorphic gene variants mainly located in the open reading frame (ORF). In the present study, we report a common polymorphism located in the 5 ' flanking region of CYP2A6 affecting its expression. DHPLC analysis and complete sequence of the open reading frame of the gene from a Turkish individual revealed a -48T > G substitution disrupting the TATA box. Using dynamic allele-specific hybridization (DASH), genotyping of this novel variant (named CYP2A6*9) was carried out in 116 Swedish, 132 Turkish, and 102 Chinese subjects, and the allele frequencies were found to be 5.2, 7.2, and 15.7%, respectively. The significance of the polymorphism was investigated by the construction of luciferase reporter plasmids containing 135 or 500 bp of the 5 ' -upstream region of the gene transfected into human hepatoma B16A2 cells. The constructs carrying the -48T > G mutation were only expressed at about 50% of the wild-type alleles. It is concluded that the CYP2A6*9 allele might be one of the most common CYP2A6 variants in Caucasians that alters the levels of enzyme expression. (C) 2001 Academic Press.
引用
收藏
页码:455 / 460
页数:6
相关论文
共 38 条
[31]   Duplications and defects in the CYP2A6 gene:: Identification, genotyping, and in vivo effects on smoking [J].
Rao, YS ;
Hoffmann, E ;
Zia, M ;
Bodin, L ;
Zeman, M ;
Sellers, EM ;
Tyndale, RF .
MOLECULAR PHARMACOLOGY, 2000, 58 (04) :747-755
[32]  
Tan W, 2001, INT J CANCER, V95, P96, DOI 10.1002/1097-0215(20010320)95:2&lt
[33]  
96::AID-IJC1017&gt
[34]  
3.0.CO
[35]  
2-2
[36]   Interindividual differences in hepatic expression of CYP3A4:: Relationship to genetic polymorphism in the 5′-upstream regulatory region [J].
Westlind, A ;
Löfberg, L ;
Tindberg, N ;
Andersson, TB ;
Ingelman-Sundberg, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 259 (01) :201-205
[37]   THE CYP2A3-GENE PRODUCT CATALYZES COUMARIN 7-HYDROXYLATION IN HUMAN LIVER-MICROSOMES [J].
YAMANO, S ;
TATSUNO, J ;
GONZALEZ, FJ .
BIOCHEMISTRY, 1990, 29 (05) :1322-1329
[38]  
YUN CH, 1991, MOL PHARMACOL, V40, P679